Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297). Methods PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177 Lu-octreotate with quantitative SPECT/CT-based dosimetry. The IA was personalized according to the glomerular filtration rate and the body surface area for the first cycle, and according to the prior renal Gy/GBq for the subsequent cycles. The prescribed renal absorbed dose of 23 Gy was reduced by 25-50% in case of significant renal or haematological impairment. Responders were allowed to receive consolidation or maintenance cycles, for each of which 6 Gy to the kidney were prescribed. We simulated the empiric PRRT regime by fixing the IA at 7.4 GBq per cycle, with the same percentage reductions as above. Radiological, molecular imaging, biochemical, and quality of life responses, as well as safety, were assessed. Results Fifty-two patients underwent 171 cycles. In 34 patients who co…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These studies have demonstrated wide interpatient variability of renal absorbed dose by a factor of 10, underscoring the importance of dosimetry.”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [61]
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Quality of life research within the EORTC—the EORTC QLQ-C30
Fayers, P., & Bottomley, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00448-8 · Cited by 924
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., Bartolomei, M., Lombardo, D., Ferrari, M. E., Sansovini, M., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1902-1 · Cited by 424
Sandström, M., Garske-Román, U., Granberg, D., Johansson, S., Widström, C., Eriksson, B., Sundin, A., Lundqvist, H., & Lubberink, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107524 · Cited by 287
Wild, D., Fani, M., Fischer, R., Del Pozzo, L., Kaul, F., Krebs, S., Fischer, R., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 266
Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
Hänscheid, H., Lapa, C., Buck, A. K., Lassmann, M., & Werner, R. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193706 · Cited by 219
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Sundlöv, A., Sjögreen-Gleisner, K., Svensson, J., Ljungberg, M., Olsson, T., Bernhardt, P., & Tennvall, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3678-4 · Cited by 209
Ezziddin, S., Khalaf, F., Vanezi, M., Haslerud, T., Mayer, K., Al Zreiqat, A., Willinek, W., Biersack, H.-J., & Sabet, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2677-3 · Cited by 189
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Sandström, M., Garske, U., Granberg, D., Sundin, A., & Lundqvist, H. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1216-8 · Cited by 182
Khan, S., Krenning, E. P., van Essen, M., Kam, B. L., Teunissen, J. J., & Kwekkeboom, D. J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087932 · Cited by 179
Claringbold, P. G., Price, R. A., & Turner, J. H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1276 · Cited by 163
Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
Beauregard, J.-M., Hofman, M. S., Pereira, J. M., Eu, P., & Hicks, R. J. (2011) · Cancer Imaging · doi:10.1102/1470-7330.2011.0012 · Cited by 148
Self-citationPrete, M. D., Buteau, F.-A., & Beauregard, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3688-2 · Cited by 131
Self-citationCescato, R., Waser, B., Fani, M., & Reubi, J. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095778 · Cited by 107
(2010) · PubMed · Cited by 102
Kesavan, M., Claringbold, P. G., & Turner, J. H. (2014) · Neuroendocrinology · doi:10.1159/000362558 · Cited by 79
Hubble, D., Kong, G., Michael, M., Johnson, V., Ramdave, S., & Hicks, R. J. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1483-4 · Cited by 72
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
Prete, M. D., Arsenault, F., Saighi, N., Zhao, W., Buteau, F.-A., Celler, A. M., & Beauregard, J. (2018) · EJNMMI Physics · doi:10.1186/s40658-018-0224-9 · Cited by 69
Self-citationChan, H. S., Konijnenberg, M. W., Daniels, T., Nysus, M., Makvandi, M., de Blois, E., Breeman, W. A., Atcher, R. W., de Jong, M., & Norenberg, J. P. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0240-5 · Cited by 67
Brieau, B., Hentic, O., Lebtahi, R., Palazzo, M., Ben Reguiga, M., Rebours, V., Maire, F., Hammel, P., Ruszniewski, P., & Fenaux, P. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0543 · Cited by 64
Sandström, M., Ilan, E., Karlberg, A. M., Johansson, S., Freedman, N., & Garske‐Román, U. (2015) · EJNMMI Physics · doi:10.1186/s40658-015-0127-y · Cited by 51
van Vliet, E. I., Krenning, E. P., Teunissen, J. J. M., Bergsma, H., Kam, B. L. R., & Kwekkeboom, D. J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.117408 · Cited by 45
Del, P. M., Buteau, F.-A., & Beauregard, J. (2016) · Endocrine Abstracts · doi:10.1530/endoabs.47.oc13 · Cited by 17
Self-citation
Cited by
Sjögreen Gleisner, K., Chouin, N., Gabina, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 252
Privé, B. M., Boussihmad, M. A., Timmermans, B., van Gemert, W. A., Peters, S. M. B., Derks, Y. H. W., van Lith, S. A. M., Mehra, N., Nagarajah, J., Heskamp, S., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06144-0 · Cited by 198
Nölting, S., Ullrich, M., Pietzsch, J., Ziegler, C. G., Eisenhofer, G., Grossman, A., & Pacak, K. (2019) · Cancers · doi:10.3390/cancers11101505 · Cited by 172
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95
“The renal dosimetry threshold has been used by studies to optimize treatment schedules by modifying the administered activity per cycle or number of cycles of (177)Lu-DOTATATE (60,61).”
MethodSundlöv, A., Gleisner, K. S., Tennvall, J., Ljungberg, M. H., Warfvinge, C. F., Holgersson, K., Hallqvist, A., Bernhardt, P., & Svensson, J. B. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05786-w · Cited by 106
Metadata
- Authors
- Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M.
- Affiliations
- Université Laval (CA)
- Centre hospitalier universitaire de Québec (CA)
- Corresponding author
- Beauregard, Jean-Mathieu
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2018-11-30
- Volume
- 46
- Issue
- 3
- Pages
- 728-742
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2902656640
- Cited by
- 184
- References
- 26
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 28 · 2023: 34 · 2022: 31 · 2021: 28 · 2020: 13 · 2019: 9 · 2018: 1
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP-142233)
- Fonds de Recherche du Québec - Santé
- Ministère de l'éducation et de l’enseignement supérieur du Québec
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- peptide receptor radionuclide therapy, 177Lu-octreotate, personalized dosimetry, glomerular filtration rate, renal dysfunction, neuroendocrine tumors, SPECT/CT dosimetry, treatment response, quality of life, hematologic toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Intestinal Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Radiometry, Safety, Stomach Neoplasms, Receptors, Peptide, Neuroendocrine Tumors, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.